Imprimis Pharma (IMMY) Reports Q2 Loss of $0.35/Share

Imprimis Pharma (NASDAQ: IMMY) reported Q2 EPS of ($0.35), versus ($0.39) reported last year. Revenue for the quarter came in at $4.9 million, versus $1.97 million reported last year.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Enhanced Group plans AI health platform launch in 2026
• Corteva Inc. (CTVA) PT Lowered to $85 at UBS Amid High Expectations